The Role of Salvage Transplantation in Patients Initially Treated With Open Versus Minimally Invasive Liver Surgery: An Intention‐to‐Treat Analysis

Giovanni B. Levi Sandri, Quirino Lai, Matteo Ravaioli, Stefano Di Sandro, Emanuele Balzano, Duilio Pagano, Paolo Magistri, Fabrizio Di Benedetto, Massimo Rossi, Salvatore Gruttadauria, Paolo De Simone, Giuseppe M.

Living Donor Liver Transplantation for Imatinib‐Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology

Carlos Benítez, Martin Inzunza, Sergio Riveros, Violeta Rivas, Marcelo Garrido, Martin Dib, Francisco Barrera, Juan P. Arab, Javiera Torres, Luis I. Cortinez, Eduardo Briceño, Juan F. Guerra, Eduardo Fernandes, Jorge A. Martínez – 4 April 2020

Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B

Stephane Daffis, Scott Balsitis, Jason Chamberlain, Jim Zheng, Rex Santos, William Rowe, Dhivya Ramakrishnan, Divya Pattabiraman, Sandra Spurlock, Ruth Chu, Don Kang, Michael Mish, Ricardo Ramirez, Li Li, Bei Li, Sarina Ma, Magdeleine Hung, Christian Voitenleitner, Changsuek Yon, Manasa Suresh, Stephan Menne, Paul Cote, William E. Delaney, Richard Mackman, Simon P. Fletcher – 4 April 2020

Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis

Alessandro Mantovani, Giorgia Beatrice, Andrea Dalbeni – 4 April 2020 – At present, there is scarce information regarding the global prevalence of chronic liver disease in individuals with coronavirus disease 2019 (COVID‐19) disease, which is becoming a global pandemic. The aim of this study was to assess the overall prevalence of chronic liver disease among patients with COVID‐19 disease by meta‐analysing data in observational studies and to investigate the relationship between liver damage and COVID‐19 disease.

Comprehensive Health‐State Utilities in Contemporary Patients With Cirrhosis

Chelsey Foster, Jad Baki, Samantha Nikirk, Sydni Williams, Neehar D. Parikh, Elliot B. Tapper – 2 April 2020 – Cost‐effectiveness analysis depends on generalizable health‐state utilities. Unfortunately, the available utilities for cirrhosis are dated, may not reflect contemporary patients, and do not capture the impact of cirrhosis symptoms. We aimed to determine health‐state utilities for cirrhosis, using both the standard gamble (SG) and visual analog scale (VAS). We prospectively enrolled 305 patients.

Subscribe to